Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells

Paolo Pedrazzoli, Giovanna Bacciocchi, Gaetano Bergamaschi, Mario Cazzola, Marco Danova, Nadia Gibelli, Monica Giordano, Antonio Lazzaro, Franco Locatelli, Lorenzo Pavesi, Gino Volpato, Carlo Zibera, Gioacchino Robustelli Della Cuna

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Nonhematopoietic malignant cells may express receptors for hematopoietic growth factors and respond to these peptides. The aim of the present study was to investigate whether small cell lung cancer (SCLC) cells may be stimulated to proliferate by hematopoietic growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), which are currently used in clinical trials in combination with cytotoxic chemotherapy. We studied two SCLC cell lines, H69 and N417. The effects of GM-CSF and IL-3 were evaluated by studying clonal growth, 3H-thymidine incorporation, BUDR/DNA bivariate flow cytometry, c-myc and N-myc oncogene expression, and myeloid surface markers. Our experiments show that both GM-CSF and IL-3 can increase 3H-thymidine incorporation and cloning efficiency and reduce DNA synthesis time of H69 and, to a lesser extent, N417 cells, supporting the hypothesis that hematopoietic growth factors can stimulate the growth of some malignant nonhematopoietic cells in vitro. Further in vitro and in vivo studies are needed to determine whether clinical trials applying these factors for bone marrow recovery after chemotherapy of solid tumors may be hazardous by potentially stimulating growth of remaining tumor tissue.

Original languageEnglish
Pages (from-to)283-288
Number of pages6
JournalCancer Investigation
Volume12
Issue number3
DOIs
Publication statusPublished - 1994

Fingerprint

Interleukin-3
Small Cell Lung Carcinoma
Granulocyte-Macrophage Colony-Stimulating Factor
Thymidine
Intercellular Signaling Peptides and Proteins
Growth
Colony-Stimulating Factor Receptors
Clinical Trials
Drug Therapy
myc Genes
DNA
Organism Cloning
Neoplasms
Flow Cytometry
Bone Marrow
Cell Line
Peptides
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells. / Pedrazzoli, Paolo; Bacciocchi, Giovanna; Bergamaschi, Gaetano; Cazzola, Mario; Danova, Marco; Gibelli, Nadia; Giordano, Monica; Lazzaro, Antonio; Locatelli, Franco; Pavesi, Lorenzo; Volpato, Gino; Zibera, Carlo; Cuna, Gioacchino Robustelli Della.

In: Cancer Investigation, Vol. 12, No. 3, 1994, p. 283-288.

Research output: Contribution to journalArticle

Pedrazzoli, Paolo ; Bacciocchi, Giovanna ; Bergamaschi, Gaetano ; Cazzola, Mario ; Danova, Marco ; Gibelli, Nadia ; Giordano, Monica ; Lazzaro, Antonio ; Locatelli, Franco ; Pavesi, Lorenzo ; Volpato, Gino ; Zibera, Carlo ; Cuna, Gioacchino Robustelli Della. / Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells. In: Cancer Investigation. 1994 ; Vol. 12, No. 3. pp. 283-288.
@article{1ca92b8f793145058e0e041c6fcc82bf,
title = "Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells",
abstract = "Nonhematopoietic malignant cells may express receptors for hematopoietic growth factors and respond to these peptides. The aim of the present study was to investigate whether small cell lung cancer (SCLC) cells may be stimulated to proliferate by hematopoietic growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), which are currently used in clinical trials in combination with cytotoxic chemotherapy. We studied two SCLC cell lines, H69 and N417. The effects of GM-CSF and IL-3 were evaluated by studying clonal growth, 3H-thymidine incorporation, BUDR/DNA bivariate flow cytometry, c-myc and N-myc oncogene expression, and myeloid surface markers. Our experiments show that both GM-CSF and IL-3 can increase 3H-thymidine incorporation and cloning efficiency and reduce DNA synthesis time of H69 and, to a lesser extent, N417 cells, supporting the hypothesis that hematopoietic growth factors can stimulate the growth of some malignant nonhematopoietic cells in vitro. Further in vitro and in vivo studies are needed to determine whether clinical trials applying these factors for bone marrow recovery after chemotherapy of solid tumors may be hazardous by potentially stimulating growth of remaining tumor tissue.",
author = "Paolo Pedrazzoli and Giovanna Bacciocchi and Gaetano Bergamaschi and Mario Cazzola and Marco Danova and Nadia Gibelli and Monica Giordano and Antonio Lazzaro and Franco Locatelli and Lorenzo Pavesi and Gino Volpato and Carlo Zibera and Cuna, {Gioacchino Robustelli Della}",
year = "1994",
doi = "10.3109/07357909409023026",
language = "English",
volume = "12",
pages = "283--288",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells

AU - Pedrazzoli, Paolo

AU - Bacciocchi, Giovanna

AU - Bergamaschi, Gaetano

AU - Cazzola, Mario

AU - Danova, Marco

AU - Gibelli, Nadia

AU - Giordano, Monica

AU - Lazzaro, Antonio

AU - Locatelli, Franco

AU - Pavesi, Lorenzo

AU - Volpato, Gino

AU - Zibera, Carlo

AU - Cuna, Gioacchino Robustelli Della

PY - 1994

Y1 - 1994

N2 - Nonhematopoietic malignant cells may express receptors for hematopoietic growth factors and respond to these peptides. The aim of the present study was to investigate whether small cell lung cancer (SCLC) cells may be stimulated to proliferate by hematopoietic growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), which are currently used in clinical trials in combination with cytotoxic chemotherapy. We studied two SCLC cell lines, H69 and N417. The effects of GM-CSF and IL-3 were evaluated by studying clonal growth, 3H-thymidine incorporation, BUDR/DNA bivariate flow cytometry, c-myc and N-myc oncogene expression, and myeloid surface markers. Our experiments show that both GM-CSF and IL-3 can increase 3H-thymidine incorporation and cloning efficiency and reduce DNA synthesis time of H69 and, to a lesser extent, N417 cells, supporting the hypothesis that hematopoietic growth factors can stimulate the growth of some malignant nonhematopoietic cells in vitro. Further in vitro and in vivo studies are needed to determine whether clinical trials applying these factors for bone marrow recovery after chemotherapy of solid tumors may be hazardous by potentially stimulating growth of remaining tumor tissue.

AB - Nonhematopoietic malignant cells may express receptors for hematopoietic growth factors and respond to these peptides. The aim of the present study was to investigate whether small cell lung cancer (SCLC) cells may be stimulated to proliferate by hematopoietic growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), which are currently used in clinical trials in combination with cytotoxic chemotherapy. We studied two SCLC cell lines, H69 and N417. The effects of GM-CSF and IL-3 were evaluated by studying clonal growth, 3H-thymidine incorporation, BUDR/DNA bivariate flow cytometry, c-myc and N-myc oncogene expression, and myeloid surface markers. Our experiments show that both GM-CSF and IL-3 can increase 3H-thymidine incorporation and cloning efficiency and reduce DNA synthesis time of H69 and, to a lesser extent, N417 cells, supporting the hypothesis that hematopoietic growth factors can stimulate the growth of some malignant nonhematopoietic cells in vitro. Further in vitro and in vivo studies are needed to determine whether clinical trials applying these factors for bone marrow recovery after chemotherapy of solid tumors may be hazardous by potentially stimulating growth of remaining tumor tissue.

UR - http://www.scopus.com/inward/record.url?scp=0028340802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028340802&partnerID=8YFLogxK

U2 - 10.3109/07357909409023026

DO - 10.3109/07357909409023026

M3 - Article

C2 - 8187006

AN - SCOPUS:0028340802

VL - 12

SP - 283

EP - 288

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -